title: Regorafenib use as a possible cause of intestinal perforation.
authors.affiliation: Centre Oscar Lambret , Lille , France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Adenis
authors.forename: Nuria
authors.initials: N
authors.lastname: Kotecki
authors.forename: Gauthier
authors.initials: G
authors.lastname: Decanter
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Clisant
authors.forename: Nicolas
authors.initials: N
authors.lastname: Penel
mesh_terms: D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced*; D008297:Male; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*
chemical_list: D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib